This contract was awarded by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to the University of Alabama at Birmingham (UAB), an internationally renowned research university and academic medical center. The contract, valued at $616,373.16, is a Firm Fixed Price Delivery Order under the "In Vitro Assessments of Antimicrobial Activity (IVAAA)" master IDIQ contract. The objective is to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in the Statement of Work, as well as other rapidly emerging viruses using the same assay methodology. This contract does not have a set-aside designation and is expected to be completed by August 28, 2023. UAB has an extensive track record of delivering biomedical and public health research under federal grants and contracts, leveraging its expertise in areas such as cancer, infectious diseases, chronic illnesses, neuroscience, and health disparities.
Generated 5/17/24, 9:40 AM